Atsena Oversubscribes $150 Million Series C to Boost Gene Therapy
Deal News | Apr 02, 2025 | Abingworth LLP
Atsena Therapeutics, a clinical-stage gene therapy firm focused on reversing and preventing blindness through genetic medicine, announced the successful closure of an oversubscribed $150 million Series C financing on April 2, 2025. The financing round was spearheaded by Bain Capital's Life Sciences division, with Wellington Management also coming on board as a new investor. Previous investors, including Abingworth, Lightstone Ventures, and others, participated as well. The capital will advance Atsena's lead program, ATSN-201, targeting X-linked retinoschisis, along with other preclinical therapeutic innovations. Aspects of the financing include significant investor and partnership support, furthering Atsena's mission of reversing inherited retinal diseases. Bain Capital highlights Atsena's potential to impact the medical scene with innovative treatments. This crucial step brings substantial advancements in Atsena's ocular gene therapies, marking a key milestone for the company's continued strategic growth.
Sectors
- Gene Therapy
- Biotechnology
- Private Equity & Venture Capital
Geography
- United States – Atsena Therapeutics is located in Durham, NC, and has U.S.-based investors participating in the financing rounds, indicating a significant U.S. presence.
Industry
- Gene Therapy – The article centers around Atsena Therapeutics, a company engaged in gene therapy to prevent and reverse blindness, a specialized area of biotech focused on genetic modification techniques.
- Biotechnology – Atsena is developing biotechnology solutions for inherited retinal diseases, thus placing it within the broader biotechnology sector.
- Private Equity & Venture Capital – The financing involves participation from private equity and venture capital firms, including Bain Capital and existing investors, indicating the relevance of this sector.
Financials
- $150 million – The total amount raised by Atsena Therapeutics in their oversubscribed Series C financing round.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Atsena Therapeutics | Target Company | Company | A clinical-stage gene therapy company focused on developing treatments for vision loss due to inherited retinal diseases. |
| Bain Capital | Investor | Company | A global investment firm leading the Series C financing round for Atsena Therapeutics. |
| Wellington Management | Investor | Company | A new investor participating in Atsena's Series C financing round. |
| Abingworth LLP | Existing Investor | Company | One of the existing investors of Atsena, specializing in life sciences investments. |
| Norbert Riedel | Board Member | Person | A seasoned scientist and biopharmaceutical executive joining Atsena's Board of Directors. |
| Patrick Ritschel | CEO | Person | Chief Executive Officer of Atsena Therapeutics, leading the company towards further growth in gene therapy. |
| Wedbush & Co. | Placement Agent | Company | Exclusive placement agent for Atsena in the Series C financing. |
| Cooley LLP | Legal Advisor | Company | Legal advisor to Atsena Therapeutics for the Series C financing. |